Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Auvelity is a prescription medicine containing dextromethorphan hydrobromide and bupropion hydrochloride in extended-release tablets. It is approved for major depressive disorder in adults and for agitation associated with dementia due to Alzheimer disease. The product is not approved for pediatric patients, and it is not used as an as-needed treatment for Alzheimer-related agitation.
read more about auvelity ...Dextromethorphan acts as an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist. Bupropion inhibits CYP2D6, which raises dextromethorphan blood concentrations, and has noradrenergic and dopaminergic activity. The exact mechanisms responsible for Auvelity treatment effects in major depressive disorder and agitation associated with Alzheimer dementia are not fully known.
Auvelity is approved for major depressive disorder in adults and for agitation associated with dementia due to Alzheimer disease. The agitation indication uses scheduled treatment rather than dosing only when agitation occurs. Before treatment, clinicians assess blood pressure, bipolar disorder history, and use of other medicines containing bupropion or dextromethorphan.
For major depressive disorder, treatment starts with 45 mg of dextromethorphan and 105 mg of bupropion once each morning, then increases on day 4 to the same dose twice daily at least eight hours apart. Alzheimer-related agitation starts at 30 mg and 105 mg once daily, with staged increases on days 8 and 15 based on tolerability.
Auvelity carries a boxed warning for suicidal thoughts and behaviors in younger people taking antidepressants. Other serious concerns include seizures, high blood pressure, mania or hypomania, psychosis, angle-closure glaucoma, dizziness, serotonin syndrome, and low blood sodium. Monoamine oxidase inhibitors, seizure disorders, and certain eating disorders are among its contraindications.
Auvelity combines dextromethorphan hydrobromide with bupropion hydrochloride in an extended-release tablet.
Yes. Auvelity is approved for major depressive disorder in adults.
Yes. It is approved for agitation associated with dementia due to Alzheimer disease and is taken on a scheduled regimen.
No. Auvelity tablets are swallowed whole and should not be crushed, divided, or chewed.
AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) Medication Guide. https://www.axsome.com/auvelity-medication-guide.pdf. Date Accessed September 14, 2026.
AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) Prescribing Information. https://www.axsome.com/auvelity-prescribing-information.pdf. Date Accessed September 14, 2026.
DailyMed - AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79. Date Accessed September 14, 2026.
Dextromethorphan and Bupropion. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622070.html. Date Accessed September 14, 2026.
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia. Date Accessed September 14, 2026.